TQA3605 / Sino Biopharm - LARVOL DELTA

TQA3605-II-02: A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=215 ➔ 0 | Trial completion date: Sep 2028 ➔ Jul 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: May 2028 ➔ Jul 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Hepatitis B • Infectious Disease • Inflammation

A Phase II Study of TQA3605 Tablet Combined with NAs versus NAs in Treating HBV-infected patients with low viral load who have been previously treated (ChiCTR) - P2 | N=120 | Recruiting | Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

New P2 trial • Hepatitis B • Infectious Disease

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects (clinicaltrials.gov) - P2 | N=215 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Hepatitis B • Infectious Disease • Inflammation

TQA3605-II-01: Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B (clinicaltrials.gov) - P1/2 | N=88 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Inflammation

TQA3605-II-01: Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B (clinicaltrials.gov) - P1/2 | N=88 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=64 ➔ 88 | Trial completion date: Dec 2024 ➔ Sep 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Combination therapy • Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation